1. Inicio
  2. Proyectos y Estudios
  3. A parallel-group treatment, Phase 2, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR444656 in adult participants with moderate to severe hidradenitis suppurativa.

A parallel-group treatment, Phase 2, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR444656 in adult participants with moderate to severe hidradenitis suppurativa.

Datos básicos

Código:
ACT17841
Protocolo:
ACT17841
EUDRACT:
NCT:
Centro:
HOSPITAL DE MANISES
Dotación:
Año de incio:
2024
Año de finalización:
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Financiadores - Promotores

PHARMACEUTICAL PRODUCT DEVELOPMENT SPAIN SL

Resultados del Ensayo Clínico

Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

Daudén E; (...); Llamas-Velasco M

Article. 10.1111/ijd.16915. 2024

  • Open Access.

Epigenetic characterization of the inflammatory hidradenitis suppurativa phenotype

Martorell, Antonio; (...); Sandoval, Juan

Meeting Abstract. 2023


Safety and Efficacy Profile of Bimekizumab in Patients With Psoriasis and Psoriatic Arthritis: An 18-Patient Case Series.

Melgosa Ramos, F J; (...); Martorell, A

Article. 10.1016/j.ad.2024.08.009. 2024

  • Open Access.

Compartir